Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCMGA00012 in Advanced/Metastatic Endometrial Cancer (China)
CTR20210608Phase 2Terminated
- Sponsor
- Incyte
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab in endometrial cancer (EC), sponsored by Incyte. Started Apr 2021; status: terminated.
02
Drugs
retifanlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20210608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210608.